Top Story

ALLY-1: transplant patients, those with cirrhosis achieve SVR12 with daclatasvir, sofosbuvir

April 26, 2015

VIENNA — A regimen containing Sovaldi and daclatasvir was associated with favorable 12-week sustained virologic response rates in a cohort of patients with advanced cirrhosis, according to data presented at the 2015 International Liver Congress.

“This 12-week pangenotypic regimen of daclatasvir, sofosbuvir and ribavirin is generally safe, well-tolerated and efficacious across multiple genotypes,” Fred Poordad, MD, of the Texas Liver Institute and University of Texas Health Science Center in San Antonio, said during the Late Breakers session.

Meeting News Coverage

Oligonucleotide injection reduced HCV viral load

April 26, 2015
VIENNA — Injection of an oligonucleotide with activity against microRNA-122 led to undetectable viral load in a cohort of HCV patients of multiple genotypes…
ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1 Meeting News Coverage

ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1

April 25, 2015
VIENNA — Patients treated with regimens containing Sovaldi and daclatasvir achieved encouraging 4-week sustained virologic response rates, according to data…
Meeting News Coverage

RUBY-I: Preliminary study shows safety of 3D + ribavirin in CKD

April 25, 2015
VIENNA — A small cohort of patients with chronic kidney disease demonstrated favorable tolerability outcomes with the Viekira Pak, according to data presented…
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News Coverage Video
thumbnail for video 3899432251001

New HCV treatments could reduce mortality, but increase costs by billions

November 19, 2014
BOSTON – In this video exclusive from The Liver Meeting, David B. Rein, PhD, MPA, of the National Opinion…
More »
Meeting News Coverage

ALLY-1: transplant patients, those with cirrhosis achieve SVR12 with daclatasvir, sofosbuvir

April 26, 2015
VIENNA — A regimen containing Sovaldi and daclatasvir was associated with favorable 12-week sustained virologic response rates in a cohort of…
Meeting News Coverage

Oligonucleotide injection reduced HCV viral load

April 26, 2015
VIENNA — Injection of an oligonucleotide with activity against microRNA-122 led to undetectable viral load in a cohort of HCV patients of…
ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1 Meeting News Coverage

ANRS CO22: SVR4 rates near 100% for sofosbuvir/daclatasvir in genotype 1

April 25, 2015
VIENNA — Patients treated with regimens containing Sovaldi and daclatasvir achieved encouraging 4-week sustained virologic response rates…
Meeting News Coverage

RUBY-I: Preliminary study shows safety of 3D + ribavirin in CKD

April 25, 2015
VIENNA — A small cohort of patients with chronic kidney disease demonstrated favorable tolerability outcomes with the Viekira Pak, according to…
Meeting News Coverage

REP 2139 found to reduce HBsAg in Caucasians with HBV/HDV coinfection

April 25, 2015
VIENNA — In a phase 2 clinical trial, the nucleic acid polymer REP 2139 reduced hepatitis B surface antigen serum in Caucasian patients with…
Meeting News Coverage

BOSON: Sovaldi plus PEG-RBV improved SVR12 in genotype 3 HCV

April 25, 2015
VIENNA — Twelve weeks of therapy with Sovaldi plus peginterferon and ribavirin was associated with 12-week sustained virologic response rates…
Meeting News Coverage

Statin use in HCV patients may lower risk of death, decompensation

April 25, 2015
VIENNA — Statin use in patients with hepatitis C virus and compensated cirrhosis seems to offer a protective effect against death and…
Meeting News Coverage

Harvoni induces high response rates in genotype 4, 5 HCV

April 25, 2015
VIENNA — Patients with genotype 4 and 5 hepatitis C virus benefitted from treatment with Harvoni, according to findings presented at the 2015…
VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR Meeting News CoverageVideo

VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR

April 25, 2015
VIENNA — Howard Monsour Jr., MD, chief of hepatology, Houston Methodist Hospital, Texas, discussed results of the C-SURFER trial, where 99% of…
Meeting News Coverage

C-SWIFT: 8 weeks of therapy may be possible with grazoprevir/elbasvir

April 25, 2015
VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir…
More Headlines »
morganatic-roan